FDA warning letter to SwissChems over semaglutide and retatrutide
The FDA warned SwissChems that its semaglutide and retatrutide products — sold as research chemicals but promoted for human weight and metabolic use — are unapproved new drugs and misbranded under the FD&C Act. It is one of a series of letters the agency has issued to vendors offering GLP-1 and research peptides directly to the public.
Source
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024The issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.
Compounds affected
Ranked vendors for Semaglutide
Every vendor and price for Semaglutide →- 1
Amino Club$5.00/mg listed · 0 Semaglutide certificates90.1of 100Extensively documentedVisit Amino Club - 2
Ascend Science1 Semaglutide certificate88.9of 100Extensively documentedVisit Ascend Science - 3NLNorthline Labs$4.50/mg listed · 1 Semaglutide certificate87.7of 100Extensively documentedVisit Northline Labs
Ranked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. A regulatory action against a vendor is recorded on that vendor's profile and counts against its score.
Ranked vendors for Retatrutide
Every vendor and price for Retatrutide →- 1
Origin Labs5 Retatrutide certificates96.9of 100Extensively documentedVisit Origin Labs - 2
Next Gen Peptides$4.00/mg listed · 16 Retatrutide certificates93.6of 100Extensively documentedVisit Next Gen Peptides - 3Ascend Science$5.60/mg listed · 6 Retatrutide certificates91.3of 100Extensively documentedVisit Ascend Science
Ranked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. A regulatory action against a vendor is recorded on that vendor's profile and counts against its score.